Moxaverine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Moxaverine
Moxaverine structure.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.031.003 Edit this at Wikidata
Chemical and physical data
FormulaC20H21NO2
Molar mass307.393 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,[1] and on its influence on the rheological properties of red blood cells.[2]

Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.[3] The ocular efficacy of moxaverine has been explored in the clinic.[4]

References[edit]

  1. ^ Mannhold R (December 1988). "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittel-Forschung. 38 (12): 1806–8. PMID 2854468.
  2. ^ Schmid-Schönbein H, Schröder S, Grebe R, Artmann G, Eschweiler H, Teitel P (May 1988). "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittel-Forschung. 38 (5): 710–6. PMID 3415714.
  3. ^ Pemp B, Garhofer G, Lasta M, Schmidl D, Wolzt M, Schmetterer L (March 2012). "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmologica. 90 (2): 139–45. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253.
  4. ^ Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov